CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Voriconazole

Voriconazole

Last Updated: August 24, 2004

Result type: Reports

Project Number: SR0020-000

Product Line: Reimbursement Review

Generic Name: Voriconazole

Brand Name: VFEND

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Aspergillosis, Invasive

Indications: Aspergillosis, Invasive

Submission Type: Initial

Project Status: Withdrawn

Voriconazole

Files